Eli Lilly reported a strong quarter beating revenue and earnings estimates, driven by its dominant GLP-1 obesity and diabetes drugs Mounjaro and Zepbound. Despite this, the stock fell 7.2% over the past month due to pricing pressures and competition. Citigroup remains bullish with a $1,600 price target, expecting continued growth from new drugs and expanded Medicare coverage. Investors face risks from pricing and regulatory delays but the stock offers a compelling entry point with potential 37% gains.
Eli Lilly's stock price on Pluang is USD 1,147.20 as of Sep 22, 2026 18:51 WIB, down 1.48% in one day and below its 52-week high of USD 1,280 but well above the 52-week low of USD 714.59. Despite a recent 7.2% monthly decline noted in the news, the stock remains valued at over a trillion dollars in market cap on Pluang. The platform shows a typical hold time of 93 days and a dividend yield of 0.59%, with more sellers (66%) than buyers (34%) currently active.
Since Medicare began covering obesity drugs in July, 700,000 new seniors have started GLP-1 treatments, with 70% using Eli Lilly's medicines. The coverage, part of a temporary "Bridge" program, allows eligible seniors to access weight loss drugs for ...
Eli Lilly reported a remarkable 48% revenue growth driven by strong sales of Mounjaro and Zepbound, yet its stock price remains nearly flat this year. Despite recent stock volatility due to price cuts, acquisition charges, and competition concerns, a...
Novo Nordisk's shares fell over 7% after the company announced long-term targets that failed to reassure investors about competition in the weight-loss drug market. The Danish drugmaker plans to launch multiple blockbuster drugs by 2030 and aims for ...
Nvidia and Eli Lilly both exceeded earnings expectations, but Nvidia's AI-driven data center growth offers a stronger long-term investment opportunity. Nvidia posted $96.22 billion in revenue, driven by AI infrastructure demand and supply constraints...
Novo Nordisk's stock fell 7% following its capital markets day where it outlined a growth plan that aligns with industry peers rather than exceeding them, signaling slower future growth. The company highlighted the upcoming loss of U.S. patent exclus...
